The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Boston Scientific beat expectations on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue shrank slightly and GAAP earnings per share shrank significantly.
Gross margins grew, operating margins expanded, net margins dropped.
Boston Scientific booked revenue of $1.82 billion. The 22 analysts polled by S&P Capital IQ looked for a top line of $1.76 billion on the same basis. GAAP reported sales were 1.5% lower than the prior-year quarter's $1.85 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.11. The 23 earnings estimates compiled by S&P Capital IQ forecast $0.11 per share. GAAP EPS of $0.04 for Q4 were 43% lower than the prior-year quarter's $0.07 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 66.4%, 340 basis points better than the prior-year quarter. Operating margin was 12.7%, 100 basis points better than the prior-year quarter. Net margin was 3.3%, 250 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $1.79 billion. On the bottom line, the average EPS estimate is $0.10.
Next year's average estimate for revenue is $7.12 billion. The average EPS estimate is $0.43.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 749 members out of 934 rating the stock outperform, and 185 members rating it underperform. Among 185 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 164 give Boston Scientific a green thumbs-up, and 21 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Boston Scientific is hold, with an average price target of $6.38.
Is Boston Scientific the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Boston Scientific to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.